Procter & Gamble Hygiene & Health Care Ltd Q4 FY25 + FY24: Whisper Shouts, Vicks Sniffs, Old Spice Flexes – ₹4,311 Cr Sales, 26% Margins, P/E 53.5 – Is Premium Always Pricey?
1. At a Glance
PGHH is the FMCG stock that makes retail investors whisper in awe and sneeze at its valuation. With a market cap of ₹44,302 Cr and CMP ₹13,648, the stock trades at a lofty P/E of 53.5. In FY24, sales stood at ₹4,311 Cr, net profit ₹829 Cr, and OPM an elite 26%. Dividend payout? 89%—basically, P&G India is an ATM for shareholders. Whisper dominates with 50%+ market share in sanitary pads, Vicks commands over 50% in cough/cold, and Old Spice… well, at least makes Instagram reels smell nicer. But sales growth crawled at 2.5%, even as profit growth hit 22.8% TTM. Returns? 1-year: -17%, 3-year: flat, 5-year: +7%. Basically, Whisper pads are growing faster than the company.
2. Introduction
PGHH is that posh kid in your colony—rich, premium, always immaculately dressed, but a bit slow at the race. Incorporated as Richardson Hindustan in 1964, acquired by P&G in 1985, it is now India’s premium play in femcare and healthcare. The company doesn’t just sell pads and vaporub, it sells category dominance. Whisper = cultural synonym for sanitary pads. Vicks = childhood memory of every Indian mom rubbing balm on your chest during flu. Old Spice = nostalgia for your dad’s shaving cabinet.
But here’s the twist: revenue growth is slower than the line at an SBI branch, while profitability and ROE are shooting through the roof—ROE at 75.7%, ROCE at a comical 104%. Translation: This is a cash-spewing FMCG god, but it refuses to scale like peers Dabur, Godrej, or Colgate. Investors pay 53× earnings because they’re betting “monopoly margins” will outshine sluggish sales. The stock, however, has underperformed badly—down 17% in a year. Which begs the question: are you buying Whisper’s whisper, Vicks’ vapor, or just P&G’s brand halo?
3. Business Model – WTF Do They Even Do?
Think of PGHH as a two-engine jet with a small afterburner:
Whisper (70% revenue): Ultra Clean, Ultra Softs, Bindazzz Nights, Daily Liners, and now Period Panties. Basically, Whisper doesn’t whisper—it shouts market dominance with 50%+ share. Double-digit growth expected in femcare for the next 3 years.
Vicks (30% revenue): VapoRub, Inhaler, Throat Drops, Action 500 Advanced, Baby Rub, ZzzQuil (sleep supplement). Basically, a pharmacy’s cash counter. Every Indian flu season is PGHH’s bonus season.
Old Spice: A rounding error in revenue, but great for “brand recall.” Let’s be honest—it’s more popular in memes than in sales.
New launches include Vicks Steam Pods, Vicks Roll On, Whisper Ultra XL Heavy Flow. In short: PGHH monetizes your blocked nose, cramps, and dad’s deo.
Question to readers: If 70% of revenue is from sanitary pads, does that make PGHH more of a Whisper Ltd than P&G?
Commentary: Profit doubled YoY because last year had impairment and tax hit. Revenue growth? Basically flat. Whisper pads are expanding faster than their topline.
